Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 21918421)

1.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Ford N, Calmy A, Mofenson L.

AIDS. 2011 Nov 28;25(18):2301-4. doi: 10.1097/QAD.0b013e32834cdb71. Review.

PMID:
21918421
2.

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.

Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, Calmy A.

AIDS. 2010 Jun 19;24(10):1461-70. doi: 10.1097/QAD.0b013e32833a2a14. Review.

PMID:
20479637
3.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Shaffer N, Renaud F.

AIDS. 2014 Mar;28 Suppl 2:S123-31. doi: 10.1097/QAD.0000000000000231. Review.

PMID:
24849471
4.

Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.

Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S, Majeke B.

AIDS. 2010 Jan 16;24(2):283-9. doi: 10.1097/QAD.0b013e328333af32.

PMID:
19864931
5.

Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.

Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, Sansone M, Fiscon M, Liuzzi G, Guerra B, Vimercati A, Vichi F, Vicini I, Pinnetti C, Marconi AM, Ravizza M; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

BJOG. 2013 Nov;120(12):1466-75. doi: 10.1111/1471-0528.12285. Epub 2013 May 31.

PMID:
23721372
6.

[Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients].

Jeantils V, Khuong MA, Delassus JL, Honoré P, Taverne B, Uzan M, Tassi S.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):593-6. Epub 2006 Jun 30. French.

PMID:
16814587
7.

Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.

Hsu HE, Rydzak CE, Cotich KL, Wang B, Sax PE, Losina E, Freedberg KA, Goldie SJ, Lu Z, Walensky RP; CEPAC Investigators.

HIV Med. 2011 Feb;12(2):97-108. doi: 10.1111/j.1468-1293.2010.00856.x.

8.

Periconceptional exposure to efavirenz and neural tube defects.

De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G.

Arch Intern Med. 2002 Feb 11;162(3):355. No abstract available.

PMID:
11822930
9.

Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana.

Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, DeGruttola SM, Makhema J, Essex M, Marlink RG.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):269-73.

PMID:
17450102
10.

Risk of birth defects associated with nelfinavir exposure during pregnancy.

Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM.

Obstet Gynecol. 2004 Jun;103(6):1181-9.

PMID:
15172850
11.

Lopinavir/ritonavir in pregnancy.

Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):456-61. doi: 10.1097/QAI.0b013e3181a2813f.

PMID:
19381099
12.

Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.

Esker S, Albano J, Uy J, Arikan D, Jimenez-Exposito MJ, Seekins D, Tilson H.

AIDS Patient Care STDS. 2012 Jun;26(6):307-11. doi: 10.1089/apc.2011.0444. Epub 2012 Mar 9. No abstract available.

PMID:
22404239
13.

Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study.

Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):299-305.

PMID:
17159659
14.

Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry.

White A, Eldridge R, Andrews E.

Acta Paediatr Suppl. 1997 Jun;421:86-8.

PMID:
9240865
15.

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, Conway D, Sperling RS, Spiegel H, Van Dyke RB.

Pediatr Infect Dis J. 2010 Aug;29(8):721-7. doi: 10.1097/INF.0b013e3181e74a2f.

16.

Pregnancy category change for efavirenz.

[No authors listed]

AIDS Patient Care STDS. 2005 Jun;19(6):413. No abstract available.

PMID:
15989437
17.

Preliminary results on pregnancy outcomes in women using lamotrigine.

Tennis P, Eldridge RR; International Lamotrigine Pregnancy Registry Scientific Advisory Committee.

Epilepsia. 2002 Oct;43(10):1161-7.

PMID:
12366730
18.

Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA.

AIDS. 2012 Mar 13;26(5):625-34. doi: 10.1097/QAD.0b013e328350fbfb.

19.

Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.

Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA; National Birth Defects Prevention Study.

Birth Defects Res A Clin Mol Teratol. 2012 Jan;94(1):22-30. doi: 10.1002/bdra.22865. Epub 2011 Nov 19.

20.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk